European Lung Cancer Congress

Martin Reck, MD, PhD, head of the department of thoracic oncology at Lung Clinic Grosshansdorf, discusses the rationale for the IMpower150 study.

Luis G. Paz-Ares, MD, PhD, chief physician at the Hospital Universitario Doce De Octubre, discusses an integrated analysis of patients with NTRK fusion–positive non–small-cell lung cancer enrolled in the STARTRK-2, STARTRK-1, and ALKA-372-001 trials, which evaluated the safety and efficacy of entrectinib in patients with solid tumors.

Patients with ROS1-positive non–small cell lung cancer showed high response rates and durable responses following treatment with entrectinib.

Patient reported outcomes according to PD-L1 expression did not show clinically meaningful differences in quality of life with either durvalumab or placebo in patients with stage III non–small cell lung cancer, according to a retrospective analysis of the phase III PACIFIC study.

The initial overall survival analysis of the phase III MYSTIC trial of first-line durvalumab (Imfinzi) alone or in combination with tremelimumab compared with platinum-based chemotherapy in patients with metastatic non–small cell lung cancer, may have been confounded by high rates of post-study immunotherapy given in the control arm.

Antonio Passaro, MD, PhD, of the Division of Thoracic Oncology, European Institute of Oncology, discusses a study that sought to determine the factors that have an impact on 5-year survival among patients treated for metastatic non–small cell lung cancer using ALK TKIs.

Larotrectinib showcased an overall response rate of 71% in patients with non–small cell lung cancer harboring NTRK gene fusions.

Leora Horn, MD, MSc, associate professor of cancer research, Vanderbilt University Medical Center, discusses the use of circulating tumor DNA analysis as a means to monitor response to, as well as resistance to, ensartinib in patients with ALK–positive non–small cell lung cancer.

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the significance of the phase III results of the FLAURA trial, which explored osimertinib (Tagrisso) in the frontline setting for patients with EGFR-mutant non

James CH Yang, MD, PhD, Professor of Medicine, Deputy Director, Department of Medical Oncology, National Taiwan University Hospital, Director, Cancer Research, Center National Taiwan University College of Medicine, discusses resistance mechanisms that develop from treatment with osimertinib (Tagrisso) and other EGFR tyrosine kinase inhibitors (TKIs). Yang discussed this in an interview during the 2018 European Lung Cancer Congress, which is a joint collaboration between ESMO and the IASLC.

First-line treatment with osimertinib resulted in a clinically meaningful delay in time from randomization to second progression on subsequent treatment or death, establishing the agent as a new standard of care in the frontline setting for patients with EGFR-mutant non–small cell lung cancer.

Benjamin Besse, MD, Institut Gustave Roussy, Villejuif, Paris Sud University, discusses challenges facing the treatment of patients with stage IV non

Martin Reck, MD, Department of Thoracic Oncology, Lung Clinic Grosshansdorf, discusses the IMpower150 trial data for patients with non

A phase Ib study of necitumumab in combination with abemaciclib failed to meaningfully improve outcomes in patients with stage IV non–small cell lung cancer.

Patients with advanced non–small cell lung cancer and baseline central nervous system metastasis showed control of their CNS metastasis after receiving osimertinib in a real-world clinical setting.

Researchers from Japan recommended against further development of nivolumab for patients with previously treated unresectable or recurrent thymic carcinoma based on their findings from the phase II PRIMER study.

Frontline treatment with osimertinib led to similar improvements in quality of life, including a clinically meaningful improvement in cough, compared with a standard of care EGFR TKIs for patients with advanced EGFR-mutant non–small cell lung cancer.

Maurice Perol, MD, medical oncologist, Centre Leon Berard, discusses the results of the ALEX trial in ALK-positive non–small cell lung cancer.

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the CheckMate-384 study in non–small cell lung cancer.

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the quality of life findings from the FLAURA study in non–small cell lung cancer.

In findings consistent with earlier results on efficacy and adverse events reported for the phase III ALEX trial, investigators announced superior patient-reported outcomes for the next-generation tyrosine kinase inhibitor alectinib versus the standard of care TKI inhibitor crizotinib in ALK-positive non–small cell lung cancer.

The frontline regimen of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel has emerged as a potential new standard of care for the treatment of patients with metastatic nonsquamous NSCLC.

Anti PD-L1 immunotherapy with atezolizumab (Tecentriq) was strongly superior to docetaxel in locally advanced or metastatic non–small cell lung cancer, according to 3-year survival findings from the phase II POPLAR study.

Paul Baas, MD, professor, Department of Thoracic Oncology, Netherlands Cancer Institute, discusses the future of treatment in mesothelioma.

​Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, discusses PD-L1 immunohistochemistry in lung cancer.